Figure S5 MicroCT Reconstructions of skulls from Osx-Cre mice. Minor craniofacial defects are present in 5.5 week-old Osx- Cre mice. These mice are wildtype at the Hdac3 loci. Found at: doi:10.1371/journal.pone.0011492.s005 (0.35 MB TIF) Table S1 List of the 176 genes common to two independent microarray experiments. Found at: doi:10.1371/journal.pone.0011492.s006 (0.14 MB PDF) Acknowledgments We thank Dr. Teresa Hefferan, Ms. Glenda Evans, and Mr. James Herrick of the Mayo Clinic Biomaterials and Quantitative Histomorphometry Core References 1. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, et al. (1997) Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89: 755–764. 2. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, et al. (1997) Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89: 765–771. 3. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, et al. (2002) The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108: 17–29. 4. Khosla S, Westendorf JJ, Oursler MJ (2008) Building bone to reverse osteoporosis and repair fractures. J Clin Invest 118: 421–428. 5. Kobayashi H, Gao Y, Ueta C, Yamaguchi A, Komori T (2000) Multilineage differentiation of Cbfa1-deficient calvarial cells in vitro. Biochem Biophys Res Commun 273: 630–636. 6. Enomoto H, Furuichi T, Zanma A, Yamana K, Yoshida C, et al. (2004) Runx2 deficiency in chondrocytes causes adipogenic changes in vitro. J Cell Sci 117: 417–425. 7. Haberland M, Montgomery RL, Olson EN (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10: 32–42. 8. Lagger G, O’Carroll D, Rembold M, Khier H, Tischler J, et al. (2002) Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. Embo J 21: 2672–2681. 9. Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, et al. (2007) Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 21: 1790–1802. 10. Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, et al. (2007) Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 13: 324–331. 11. Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, et al. (2008) Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 30: 61–72. 12. Montgomery RL, Potthoff MJ, Haberland M, Qi X, Matsuzaki S, et al. (2008) Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 118: 3588–3597. 13. Haberland M, Mokalled MH, Montgomery RL, Olson EN (2009) Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes Dev 23: 1625–1630. 14. Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, et al. (2004) Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119: 555–566. 15. Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S, et al. (2008) Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 28: 1688–1701. 16. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, et al. (2004) Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24: 8467–8476. 17. Chang S, Young BD, Li S, Qi X, Richardson JA, et al. (2006) Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 126: 321–334. 18. Fischle W, Dequiedt F, Fillion M, Hendzel MJ, Voelter W, et al. (2001) Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem 276: 35826–35835. 19. Fischle W, Dequiedt F, Hendzel MJ, Guenther MG, Lazar MA, et al. (2002) Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 9: 45–57. 20. Guenther MG, Barak O, Lazar MA (2001) The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol 21: 6091–6101. 21. Guenther MG, Lane WS, Fischle W, Verdin E, Lazar MA, et al. (2000) A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev 14: 1048–1057. Hdac3 Regulates Bone Density Laboratory for their help with the histomorphometry experiments. We also thank Dr. Yan Asmann, Ying Li, and Zhifu Sun for providing the statistical and bioinformatics analyses on microarray data. Author Contributions Conceived and designed the experiments: DFR MEML JJW. Performed the experiments: DFR TJW MEC MEML BAS XL FJS. Analyzed the data: DFR TJW MEC MEML XL JJW. Contributed reagents/materials/ analysis tools: SKK SWH. Wrote the paper: DFR SWH JJW. 22. Guenther MG, Yu J, Kao GD, Yen TJ, Lazar MA (2002) Assembly of the SMRT-histone deacetylase 3 repression complex requires the TCP-1 ring complex. Genes Dev 16: 3130–3135. 23. Westendorf JJ (2007) Histone deacetylases in control of skeletogenesis. J Cell Biochem. 24. Schroeder TM, Kahler RA, Li X, Westendorf JJ (2004) Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem 279: 41998–42007. 25. Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, et al. (2002) Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol 22: 7982–7992. 26. Jensen ED, Schroeder TM, Bailey J, Gopalakrishnan R, Westendorf JJ (2008) Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner. J Bone Miner Res 23: 361–372. 27. Makita N, Suzuki M, Asami S, Takahata R, Kohzaki D, et al. (2008) Two of four alternatively spliced isoforms of RUNX2 control osteocalcin gene expression in human osteoblast cells. Gene 413: 8–17. 28. Choo MK, Yeo H, Zayzafoon M (2009) NFATc1 mediates HDAC-dependent transcriptional repression of osteocalcin expression during osteoblast differenti- ation. Bone. 29. Lamour V, Detry C, Sanchez C, Henrotin Y, Castronovo V, et al. (2007) Runx2- and histone deacetylase 3-mediated repression is relieved in differen- tiating human osteoblast cells to allow high bone sialoprotein expression. J Biol Chem 282: 36240–36249. 30. Rodda SJ, McMahon AP (2006) Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 133: 3231–3244. 31. Knutson SK, Chyla BJ, Amann JM, Bhaskara S, Huppert SS, et al. (2008) Liver- specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. Embo J 27: 1017–1028. 32. Kaback LA, Soung do Y, Naik A, Smith N, Schwarz EM, et al. (2008) Osterix/ Sp7 regulates mesenchymal stem cell mediated endochondral ossification. J Cell Physiol 214: 173–182. 33. Petit MA, Beck TJ, Kontulainen SA (2005) Examining the developing bone: What do we measure and how do we do it? J Musculoskelet Neuronal Interact 5: 213–224. 34. Rosen CJ, Ackert-Bicknell C, Rodriguez JP, Pino AM (2009) Marrow fat and the bone microenvironment: developmental, functional, and pathological implica- tions. Crit Rev Eukaryot Gene Expr 19: 109–124. 35. Sambucetti LC, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, et al. (1999) Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiprolif- erative effects. J Biol Chem 274: 34940–34947. 36. Richon VM, Sandhoff TW, Rifkind RA, Marks PA (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97: 10014–10019. 37. Han JW, Ahn SH, Park SH, Wang SY, Bae GU, et al. (2000) Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res 60: 6068–6074. 38. Wise LD, Turner KJ, Kerr JS (2007) Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. Birth Defects Res B Dev Reprod Toxicol 80: 57–68. 39. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817–825. 40. Kawase T, Ohki R, Shibata T, Tsutsumi S, Kamimura N, et al. (2009) PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell 136: 535–550. 41. Zupkovitz G, Tischler J, Posch M, Sadzak I, Ramsauer K, et al. (2006) Negative and positive regulation of gene expression by mouse histone deacetylase 1. Mol Cell Biol 26: 7913–7928. 42. Bellosta P, Masramon L, Mansukhani A, Basilico C (2003) p21(WAF1/CIP1) acts as a brake in osteoblast differentiation. J Bone Miner Res 18: 818–826. PLoS ONE | www.plosone.org 14 July 2010 | Volume 5 | Issue 7 | e11492